MorphoSys Appoints Dr Arndt Schottelius as Chief Development Officer and Member of the Management Board
During his career Dr Schottelius has established a successful track record of advancing therapeutics from late stage research into clinical development. He has gathered extensive experience in discovery and in-licensing activities, portfolio management, pre-clinical and clinical development as well as FDA negotiations and regulatory filings. After medical studies in Germany, the United Kingdom and Switzerland Dr Schottelius received his PhD and MD degrees from the Albert-Ludwigs-University, Freiburg, Germany. Subsequently he practiced medicine as a resident physician in gastroenterology at the Charité University Hospital, Berlin, Germany, and held a research fellowship from the Crohn's & Colitis Foundation of America at the University of North Carolina at Chapel Hill before moving into the pharmaceutical industry.
Topics
Organizations
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous